Literature DB >> 24649335

Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer.

Yoshihito Yokoyama1, Masayuki Futagami1, Jun Watanabe2, Naoki Sato3, Yukihiro Terada3, Fumiharu Miura4, Toru Sugiyama4, Tadao Takano5, Nobuo Yaegashi5, Takanobu Kojimahara6, Hirohisa Kurachi6, Hiroshi Nishiyama7, Keiya Fujimori7, Toru Tase8, Hideki Mizunuma1.   

Abstract

The standard postoperative chemotherapy for epithelial ovarian cancer is a combination therapy including platinum and taxanes. The aim this study was to investigate the degree of platinum sensitivity in patients with relapsed epithelial ovarian cancer according to the treatment-free interval (TFI) and the histological tumor type. The medical records of 405 patients diagnosed with stage III/IV ovarian cancer, including 107 patients who relapsed after attaining a clinical complete response with first-line treatment, were retrospectively reviewed. The degree of platinum sensitivity was assessed by comparing the progression-free survival (PFS) following the second-line treatment. In patients with serous/endometrioid adenocarcinoma who were treated with platinum following relapse, there were significant differences in the PFS between the following groups of patients: those who relapsed within 6 months and those who relapsed between 6 and 12 months; those who relapsed between 6 and 12 months and those who relapsed between 12 and 18 months; and those who relapsed between 12 and 18 months and those who relapsed after 18 months. By contrast, in patients with clear cell/mucinous adenocarcinoma who were treated with platinum following a relapse, there were no significant differences in the PFS between patients who relapsed within 6 months and those who relapsed between 6 and 12 months, while there were significant differences in the PFS between those who relapsed between 6 and 12 months and those who relapsed after 12 months. With regard to the patients who relapsed after 12 months, the PFS of those with clear cell/mucinous adenocarcinoma was significantly shorter compared with the PFS of those with serous/endometrioid adenocarcinoma. Therefore, we considered it justified to classify patients with clear cell/mucinous adenocarcinoma who relapsed within 12 months as platinum-resistant and those who relapsed after 12 months as platinum-sensitive.

Entities:  

Keywords:  histological type; platinum sensitivity; progression-free interval; relapsed epithelial ovarian cancer; treatment-free interval

Year:  2013        PMID: 24649335      PMCID: PMC3917783          DOI: 10.3892/mco.2013.223

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  16 in total

1.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

Authors:  M Markman; B Reichman; T Hakes; W Jones; J L Lewis; S Rubin; L Almadrones; W Hoskins
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

3.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

Authors:  M E Gore; I Fryatt; E Wiltshaw; T Dawson
Journal:  Gynecol Oncol       Date:  1990-02       Impact factor: 5.482

5.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

6.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

7.  Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.

Authors:  Paul J Hoskins; Nhu Le; Blake Gilks; Anna Tinker; Jennifer Santos; Frances Wong; Kenneth D Swenerton
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

8.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

9.  Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?

Authors:  Carolyn McCourt; Sybil Dessie; Ann Marie Bradley; Joanna Schwartz; Laurent Brard; Don S Dizon
Journal:  Int J Gynecol Cancer       Date:  2009-04       Impact factor: 3.437

10.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

Authors:  G Blackledge; F Lawton; C Redman; K Kelly
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more
  6 in total

1.  Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models.

Authors:  A Kobayashi; Y Yokoyama; Y Osawa; R Miura; H Mizunuma
Journal:  Cancer Gene Ther       Date:  2015-11-20       Impact factor: 5.987

2.  Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.

Authors:  Hiroe Oikiri; Yoshiya Asano; Michiya Matsusaki; Mitsuru Akashi; Hiroshi Shimoda; Yoshihito Yokoyama
Journal:  Mol Biol Rep       Date:  2019-04-25       Impact factor: 2.316

3.  The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer.

Authors:  Yoko Matsushita; Yoshihito Yokoyama; Hidemi Yoshida; Yuki Osawa; Makito Mizunuma; Tatsuhiko Shigeto; Masayuki Futagami; Tadaastu Imaizumi; Hideki Mizunuma
Journal:  J Ovarian Res       Date:  2014-11-26       Impact factor: 4.234

4.  Predicting Long-Term Prognoses and Grading Platinum Sensitivity Using a Novel Progression-Free Interval Criterion in Ovarian Clear Cell Carcinoma: A Multi-Institutional Cohort Study.

Authors:  Cheng-Yang Chou; Wen-Fang Cheng; Min-Yu Chen; Hao Lin; Chih-Ming Ho; Yao-Ching Hung; Lee-Wen Huang; Po-Hui Wang; Mu-Hsien Yu; Yu-Fang Huang
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.639

5.  Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.

Authors:  Nair A Bonito; Jane Borley; Charlotte S Wilhelm-Benartzi; Sadaf Ghaem-Maghami; Robert Brown
Journal:  Clin Cancer Res       Date:  2016-01-13       Impact factor: 12.531

Review 6.  Biological functions and role of CCN1/Cyr61 in embryogenesis and tumorigenesis in the female reproductive system (Review).

Authors:  Rui Yang; Ying Chen; Daozhen Chen
Journal:  Mol Med Rep       Date:  2017-10-26       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.